Fig 1.
Selection of baseline study cohort.
Table 1.
Baseline demographic characteristics of the cohort of participants followed-up.
Table 2.
Seroconversion/-reversion prevalence in participants followed up.
Table 3.
First follow-up–time and additional IVM intake effects on FTS-CFA.
Table 4.
Second follow-up–time and additional IVM intake effects on FTS-CFA.
Table 5.
First follow-up–time and additional IVM intake effects on Og4C3 CFA.
Fig 2.
Changes in FTS-CFA status during first and second follow-ups between a period of 8–13 months (McNemar test). One participant who was CFA-negative from baseline became positive at first follow-up but became negative again at the second follow-up.
Fig 3.
Changes in the Og4C3 antigen levels in baseline FTS-CFA positive participants followed-up (A) individuals positive at both baseline and first follow-up (n = 49) (B) participants positive at baseline but either positive or negative at first follow-up (n = 120).
Antigen unit axis expressed in log10 scale. Wilcoxon signed rank test.
Fig 4.
Og4C3 CFA baseline status changes during first follow-up.
McNemar-Bowker test.
Fig 5.
Changes in Og4C3 antigen levels for (A) individuals positive at both baseline and first follow-up (n = 29) (B) participants positive at baseline but either positive or negative at first follow-up (n = 44).
Antigen unit axis expressed in log10 scale. Wilcoxon signed rank test.
Table 6.
Baseline and first follow-up CFA and MF characteristics of previous MF positives.